Literature DB >> 25035397

Osteopontin shapes immunosuppression in the metastatic niche.

Sabina Sangaletti1, Claudio Tripodo2, Sara Sandri1, Ilaria Torselli1, Caterina Vitali1, Chiara Ratti1, Laura Botti1, Alessia Burocchi1, Rossana Porcasi2, Andrea Tomirotti1, Mario P Colombo3, Claudia Chiodoni3.   

Abstract

The matricellular protein osteopontin (OPN, Spp-1) is widely associated with cancer aggressiveness when produced by tumor cells, but its impact is uncertain when produced by leukocytes in the context of the tumor stroma. In a broad study using Spp1(-/-) mice along with gene silencing in tumor cells, we obtained evidence of distinct and common activities of OPN when produced by tumor or host cells in a spontaneously metastatic model of breast cancer. Different cellular localization of OPN is associated with its distinct activities, being mainly secreted in tumor cells while intracellular in myeloid cells. OPN produced by tumor cells supported their survival in the blood stream, whereas both tumor- and host-derived OPN, particularly from myeloid cells, rendered the metastatic site more immunosuppressive. Myeloid-derived suppressor cells (MDSC) expanded with tumor progression at both primary and lung metastatic sites. Of the expanded monocytic and granulocytic cell populations of MDSCs, the monocytic subset was the predominant source of OPN. In Spp1(-/-) mice, the inhibition of lung metastases correlated with the expansion of granulocyte-oriented MDSCs. Notably, monocytic MDSCs in Spp1(-/-) mice were less suppressive than their wild-type counterparts due to lower expression of arginase-1, IL6, and phospho-Stat3. Moreover, fewer regulatory T cells accumulated at the metastatic site in Spp1(-/-) mice. Our data find correlation with lung metastases of human mammary carcinomas that are associated with myeloid cells expressing OPN. Overall, our results unveiled novel functions for OPN in shaping local immunosuppression in the lung metastatic niche. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25035397     DOI: 10.1158/0008-5472.CAN-13-3334

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

Authors:  Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

2.  Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease.

Authors:  Irun Bhan; Kelly Mosesso; Lipika Goyal; Julia Philipp; Mark Kalinich; Joseph W Franses; Melissa Choz; Rahmi Oklu; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber; Andrew X Zhu; Raymond T Chung; Martin Aryee; David T Ting
Journal:  Gastroenterology       Date:  2018-09-13       Impact factor: 22.682

3.  Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis.

Authors:  Ioanna Giopanou; Ioannis Lilis; Vassilios Papaleonidopoulos; Theodora Agalioti; Nikolaos I Kanellakis; Nikolitsa Spiropoulou; Magda Spella; Georgios T Stathopoulos
Journal:  Oncoimmunology       Date:  2016-11-18       Impact factor: 8.110

Review 4.  Metastatic niche functions and therapeutic opportunities.

Authors:  Toni Celià-Terrassa; Yibin Kang
Journal:  Nat Cell Biol       Date:  2018-07-26       Impact factor: 28.824

5.  Osteopontin and the immune system: another brick in the wall.

Authors:  Sara Caputo; Matteo Bellone
Journal:  Cell Mol Immunol       Date:  2017-10-02       Impact factor: 11.530

6.  The ins and outs of osteopontin.

Authors:  Claudia Chiodoni; Sabina Sangaletti; Claudio Tripodo; Mario P Colombo
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

7.  Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits.

Authors:  Wen Ding; Keyvan Yousefi; Stefania Goncalves; Bradley J Goldstein; Alfonso L Sabater; Amy Kloosterboer; Portia Ritter; Guerline Lambert; Armando J Mendez; Lina A Shehadeh
Journal:  JCI Insight       Date:  2018-03-22

8.  Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression.

Authors:  Ramesh Butti; Ramakrishna Nimma; Gautam Kundu; Anuradha Bulbule; Totakura V S Kumar; Vinoth Prasanna Gunasekaran; Deepti Tomar; Dhiraj Kumar; Anupama Mane; Satyajit S Gill; Tushar Patil; Georg F Weber; Gopal C Kundu
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

Review 9.  The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.

Authors:  Bo Ma; Alan Wells; Amanda M Clark
Journal:  Semin Cancer Biol       Date:  2019-07-31       Impact factor: 15.707

Review 10.  Tumor-associated macrophages and anti-tumor therapies: complex links.

Authors:  Cristina Belgiovine; Maurizio D'Incalci; Paola Allavena; Roberta Frapolli
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.